SCWorx Corp. is a technology company that specializes in data management and analytics solutions, primarily focusing on the healthcare sector
The company offers cloud-based services that enable healthcare organizations to streamline their operational processes, enhance data collection, and improve patient outcomes through better decision-making. SCWorx's solutions are designed to simplify complex data integration and provide actionable insights, all while ensuring compliance with industry regulations. By leveraging advanced analytics and technology, SCWorx aims to empower healthcare providers and organizations to optimize their performances and deliver more efficient care.
New York, NY, Dec. 12, 2024 (GLOBE NEWSWIRE) -- SCWorx Corp., a Delaware corporation (the “Company”), reminds its stockholders that its 2024 Annual Meeting of Stockholders will be held 9:00 AM EST on December 23, 2024, at the Regus Conference Room at 35 Village Rd, Suite 100, Middleton, MA 01949, as per the Proxy Material mailed to shareholders on December 6, 2024.
In a rapidly evolving marketplace, a group of innovative companies is capturing attention with groundbreaking solutions across diverse industries. From pet care and healthcare to clean energy, real estate, and advanced technology, these firms are leading the way in reshaping traditional business landscapes. Their achievements underscore the power of innovation in addressing critical market demands and creating opportunities for growth.
SCWorx shares are trading higher by 100% to $1.97 Thursday morning. The company announced it has successfully regained compliance with Nasdaq's listing standards.
NEW YORK, N.Y., Nov. 20, 2024 (GLOBE NEWSWIRE) -- SCWorx Corp. (Nasdaq: WORX) (the “Company”), a provider of data management services to healthcare providers, announced today that it has regained compliance with The Nasdaq Stock Market’s (“Nasdaq”) continued listing requirements regarding periodic reporting.
New York, NY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- SCWorx Corp (the “Company”), on November 19th, 2024 completed an equity financing with institutional investors (the “Institutional Investors” or “Investors”). In connection with the funding, the Company sold an aggregate of 232,558 shares of common stock and warrants to purchase the same number of shares of common stock, for aggregate gross proceeds of $200,000.
NEW YORK, N.Y., Aug. 23, 2024 (GLOBE NEWSWIRE) -- On August 19, 2024, the Nasdaq Stock Market notified SCWorx Corp. (the “Company”) that it has failed to satisfy a standard for continued listing, namely Nasdaq Listing Rule 5250(c)(1) (the “Rule), because the Company did not file its June 30, 2024 Quarterly Report on Form 10-Q by the due date of August 14, 2024 and because it remains delinquent in filing its Form 10-K for the period ended December 31, 2023 and its Form 10Q for the quarter ended March 31, 2024.
NEW YORK, N.Y., May 21, 2024 (GLOBE NEWSWIRE) -- On May 17, 2024, SCWorx Corp. (the “Company”) received a further notice (the “Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that, as a result of not having timely filed its Form 10-Q for the period ended March 31, 2024, and because it remains delinquent in filing its Form 10-K for the year ended December 31, 2023, the Company has failed to satisfy a standard for continued listing, namely Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic reports with the SEC.
NEW YORK, N.Y., April 23, 2024 (GLOBE NEWSWIRE) -- On April 17, 2024, SCWorx Corp. (the “Company”) received a notice (the “Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that, as a result of not having timely filed its Form 10-K for the period ended December 31, 2023 with the Securities and Exchange Commission (“SEC”), the Company has failed to satisfy a standard for continued listing, namely Nasdaq Listing Rule 5250(c)(1) , which requires timely filing of all required periodic reports with the SEC.
Shares of Lifecore Biomedical, Inc. (NASDAQLFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and board changes. Lifecore Biomedical shares dipped 31.7% to $4.91 on Wednesday.
